Management of adverse events during the treatment of chronic hepatitis C infection
Open Access
- 26 April 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 1 (2) , 54-57
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Risk Factors for Infection During Treatment with Peginterferon alfa and Ribavirin for Chronic Hepatitis CHepatology, 2010
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Pruritus AniThe Annals of The Royal College of Surgeons of England, 2008
- Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled studyGut, 2007
- Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis CGastroenterology, 2007
- Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CJournal of Hepatology, 2005
- Prophylactic SSRI during interferon alpha re‐therapy in patients with chronic hepatitis C and a history of interferon‐induced depressionJournal of Viral Hepatitis, 2005
- Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changesPsychological Medicine, 2004
- Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapyThe Lancet, 1999
- Treatment of intractable pruritus aniDiseases of the Colon & Rectum, 1990